Shanghai Xiao Fang Pharmaceutical Co., Ltd.SSE: 603207

Announcement on Convening the Q3 2025 Performance Briefing

Dec 2, 2025 · Issued by Shanghai Xiao Fang Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Dec 2, 2025

On 6ix: 6ix.com/news/announcement-on-convening-the-q3-2025-performance-briefing-1042

Announcement on Convening the Q3 2025 Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Shanghai Xiao Fang Pharmaceutical Co., Ltd. on 6ix

Earlier from Shanghai Xiao Fang Pharmaceutical

Announcement on Change of Sponsor Representative for Continuous SupervisionNov 15, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025Nov 11, 2025
Announcement on Using Some Temporarily Idle Raised Funds for Cash ManagementOct 25, 2025
Announcement on Redemption at Maturity of Idle Raised Funds Used for Cash ManagementOct 11, 2025
Announcement on Entrusting Bojimed to Develop the Traditional Chinese Medicine Class 1.1 New Drug "Compound Platycodon Tincture" (for Treating Hair Loss)Sep 26, 2025

Later from Shanghai Xiao Fang Pharmaceutical

Announcement on the Grant of Partial Reserved Restricted Stocks to Incentive Recipients under the 2025 Restricted Stock Incentive PlanDec 20, 2025
Announcement on the Reserved Granting Results of the 2025 Restricted Stock Incentive PlanFeb 4
Notice on Convening the 1st Extraordinary General Meeting in 2026Feb 13
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026Mar 3
Report for Q1 2026Apr 28

All Shanghai Xiao Fang Pharmaceutical news releases

Follow Shanghai Xiao Fang Pharmaceutical into a list and get an email when it puts out news.

Follow Shanghai Xiao Fang Pharmaceutical